基于治疗药物监测的度伐利尤单抗个体化给药:群体药代动力学与药物经济学评价
本研究基于许可方群体药代动力学模型,为NSCLC患者设计两种基于TDM的替代给药策略,并开展药物经济学评价。两种策略使98.1-99.0%患者超过预设疗效靶值,高于获批10 mg/kg每2周方案的95.4%,降低总药物暴露7-24%,消除药物浪费,人均年费用降低€25,163(22.9%)。
要点
- 基于TDM的度伐利尤单抗替代给药策略可使98.1-99.0%患者超过疗效靶值。
- 替代策略降低总药物暴露7-24%并消除药物浪费。
- 人均年费用降低€25,163(22.9%),需非劣效性研究验证。
核心结论
- 基于TDM调整度伐利尤单抗给药可在保证足够暴露的前提下节约费用、减轻医疗负担并降低环境影响。
- 所提策略的证据为非劣效性研究提供了坚实基础。
研究设计与样本
- 使用许可方开发的群体药代动力学模型,为NSCLC患者设计两种基于TDM的替代给药策略。
- 按监管标准进行计算机模拟剂量优化,调整剂量或给药间隔。
- 从医疗视角开展药物经济学评价,估算潜在费用节省。
主要发现
- 两种替代策略均达到高暴露水平,98.1-99.0%患者超过预设疗效靶值。
- 许可方预测的获批10 mg/kg每2周方案超过疗效靶值的患者比例为95.4%。
- 替代策略降低总药物暴露7-24%并消除药物浪费。
- 人均年费用平均降低€25,163(22.9%)。
关键数值与推荐
- 获批方案为10 mg/kg每2周,许可方预测95.4%患者超过预设疗效靶值。
- 替代策略使98.1-99.0%患者超过预设疗效靶值。
- 替代策略降低总药物暴露7-24%,人均年费用降低€25,163(22.9%)。
临床怎么用
- 可考虑基于TDM调整度伐利尤单抗剂量或给药间隔以减少浪费和费用。
- 实施前需开展非劣效性研究验证临床疗效。
局限性
- 研究为计算机模拟剂量优化与药物经济学评价,非临床终点研究。
- 结论需非劣效性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing use of immune checkpoint inhibitors, such as durvalumab, places a significant financial burden on healthcare systems, strains hospital capacities, and contributes to environmental concerns. OBJECTIVE: We aimed to develop alternative dosing strategies to optimize durvalumab administration, reduce unnecessary drug use, and ensure sustainable cancer care without sacrificing efficacy. METHODS: Using the population pharmacokinetic model developed by the licensing holder, we designed two alternative dosing strategies for non-small cell lung cancer based on therapeutic drug monitoring. Adjustments were made to the dose or administration interval, following regulatory standards for in silico dose optimization. A pharmacoeconomic evaluation was conducted to estimate potential cost savings from a medical perspective. RESULTS: Both alternative strategies achieved high exposure levels, with 98.1-99.0% of patients exceeding a predefined efficacy target, surpassing the 95.4% predicted by the license holder for the approved 10 mg/kg 2-weekly regimen. They also reduced overall drug exposure by 7-24% and eliminated drug wastage, resulting in an average annual cost reduction of €25,163 (22.9%) per patient. CONCLUSION: Therapeutic drug monitoring-guided adjustments for durvalumab offer a potentially cost-saving way to optimize drug use, reduce healthcare burdens, and lessen environmental impact while ensuring adequate patient exposure. Our proposal's evidence provides a solid basis for a non-inferiority study.
引用
- de Vries F, Franssen EJF, Smit AAJ, et al. TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation. Clin Pharmacokinet. 2025. PMID: 40711703. doi:10.1007/s40262-025-01555-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。